- Home
- CTO vs CRGX Comparison
CTO vs CRGX Comparison
Compare CTO & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTO
- CRGX
- Stock Information
- Founded
- CTO 1902
- CRGX 2021
- Country
- CTO United States
- CRGX United States
- Employees
- CTO N/A
- CRGX N/A
- Industry
- CTO Real Estate Investment Trusts
- CRGX
- Sector
- CTO Real Estate
- CRGX
- Exchange
- CTO Nasdaq
- CRGX Nasdaq
- Market Cap
- CTO 580.9M
- CRGX 628.6M
- IPO Year
- CTO N/A
- CRGX 2023
- Fundamental
- Price
- CTO $20.02
- CRGX $3.86
- Analyst Decision
- CTO Strong Buy
- CRGX Hold
- Analyst Count
- CTO 4
- CRGX 7
- Target Price
- CTO $21.50
- CRGX $4.67
- AVG Volume (30 Days)
- CTO 220.6K
- CRGX 1.9M
- Earning Date
- CTO 02-20-2025
- CRGX 03-20-2025
- Dividend Yield
- CTO 7.68%
- CRGX N/A
- EPS Growth
- CTO N/A
- CRGX N/A
- EPS
- CTO 0.61
- CRGX N/A
- Revenue
- CTO $118,662,000.00
- CRGX N/A
- Revenue This Year
- CTO N/A
- CRGX N/A
- Revenue Next Year
- CTO $13.12
- CRGX N/A
- P/E Ratio
- CTO $32.77
- CRGX N/A
- Revenue Growth
- CTO 16.61
- CRGX N/A
- 52 Week Low
- CTO $16.16
- CRGX $3.00
- 52 Week High
- CTO $21.15
- CRGX $33.92
- Technical
- Relative Strength Index (RSI)
- CTO 58.60
- CRGX 20.88
- Support Level
- CTO $19.29
- CRGX $3.00
- Resistance Level
- CTO $19.77
- CRGX $3.88
- Average True Range (ATR)
- CTO 0.35
- CRGX 0.92
- MACD
- CTO 0.07
- CRGX -1.00
- Stochastic Oscillator
- CTO 95.40
- CRGX 5.99
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a Florida-based real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.